Neonc Technologies Holdings, Inc. (NTHI)

NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer

NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt

NeOnc's Powerful Brain Cancer Pipeline Advances

Powerful NeOnc Brain Cancer Pipeline Advances

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier

NeOnc Charting New Nasal Route to Treating Brain Cancer

NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution

NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

Investor Determination to Beat Cancer Puts NeOnc's Novel Therapies and Patented Platform in Focus

Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test

NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data

NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors

NeOnc' Phase 2 Data Could Put Cancer on the Ropes

NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger

NeOnc's Clinical Story Is Now the Main Event

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't